Acurx Pharmaceuticals (ACXP)
NASDAQ:ACXP
Want to see ACXP full AI Analyst Report?
Earnings Data
Report Date
Aug 17, 2026After Close (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.38Last Year’s EPS
-1.89Same Quarter Last Year
Strong Buy
Based on 3 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
Overall the call conveyed materially positive clinical and IP progress: compelling Phase II efficacy with no observed recurrence among cured patients, initiation of an rCDI pilot, favorable FDA guidance that could reduce pivotal trial requirements, strengthened patent protection, supportive preclinical data, and recent financings that improved cash. Key negatives are the modest cash position relative to Phase III needs, small-scale early rCDI data requiring larger controlled trials, and remaining regulatory and design uncertainties. On balance, the positive clinical, regulatory and IP developments outweigh the operational and financing risks disclosed.Company Guidance
Strong Phase II Efficacy and No Recurrence in Cured Patients
Ibezapolstat Phase II showed a ~96% clinical cure rate and 0% recurrence among cured patients at 1 month (25/25 recurrence-free). In a subset, 5/5 patients observed out to 3 months remained recurrence-free, supporting the drug's potential to treat acute CDI and reduce recurrence.
New rCDI Clinical Program Initiated
Company launched an exploratory open-label pilot rCDI trial for multiply recurrent C. difficile patients (≥3 episodes in past 12 months), planned as a 20-patient study to inform a potential active-controlled Phase III registration trial in rCDI.
Regulatory Tailwinds: Single-Trial Guidance & LPAD Pathway
FDA published final guidance indicating one adequate and well-controlled trial plus confirmatory evidence may suffice for C. difficile registration; Acurx plans to meet with FDA and may pursue approval for rCDI under the Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD).
Strengthened Intellectual Property Portfolio
Company secured a new Korea patent covering DNA Pol IIIC inhibitors and an earlier USPTO patent (Feb 2026) extending coverage; total portfolio now includes 10 patents (5 U.S. patents plus patents in Israel, Japan, India, Australia and Korea), with at least one patent extending to December 2039 (subject to extension).
Preclinical Broad-Spectrum Potential with Microbiome Preservation
Preclinical data presented at ESCMID show DNA Pol IIIC compounds reduced MRSA tissue burden, achieved potentially therapeutic plasma levels, and preserved gut microbial diversity (distinct from linezolid), supporting broader gram-positive indication potential while sparing the microbiome.
Designations and Regulatory Incentives
Ibezapolstat has FDA QIDP and Fast Track designations for CDI; in Europe the company has SME status. All preclinical Acurx compounds are eligible for QIDP and Fast Track, which could accelerate development for gram-positive infections.
Improved Cash Position and Recent Financings
Cash at quarter end was $9.3M, up from $7.6M at Dec 31, 2025 (+22.4%). The company raised approximately $3.1M gross via its equity line during the quarter and closed a registered direct offering of 825,085 shares at $3.03 plus concurrent short-term warrants (1,650,170 shares exercisable at $2.78, immediately exercised). Registration statement for resale is now effective.
Reduced Operating Expenses and Narrower Net Loss
R&D expenses decreased to $0.3M from $0.6M (-50%), G&A decreased to $1.4M from $1.6M (-12.5%), and net loss improved to $1.7M ($0.62 per diluted share) from $2.1M ($2.15 per diluted share) — a ~19% reduction in net loss and a ~71% decrease in loss per diluted share year-over-year.
ACXP Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
ACXP Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 12, 2026 | $2.18 | $2.05 | -5.96% |
Mar 13, 2026 | $5.01 | $3.88 | -22.55% |
Nov 12, 2025 | $5.58 | $4.98 | -10.75% |
Aug 12, 2025 | $4.48 | $4.44 | -0.89% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Acurx Pharmaceuticals (ACXP) report earnings?
Acurx Pharmaceuticals (ACXP) is schdueled to report earning on Aug 17, 2026, After Close (Confirmed).
What is Acurx Pharmaceuticals (ACXP) earnings time?
Acurx Pharmaceuticals (ACXP) earnings time is at Aug 17, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ACXP EPS forecast?
ACXP EPS forecast for the fiscal quarter 2026 (Q2) is -0.38.